• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Home
  • LinkedIn
  • Twitter

  • About Us
    • Overview
    • Executive Committee
    • Board Of Directors
    • Partners
  • Science
    • Overview
    • Approach
    • Technology
      • shRNA
      • shARC Platform
    • Scientific Publications
  • Pipeline
  • Newsroom
    • Press Releases
    • Events
    • Media Center
  • Investors
    • Overview
    • Analyst Coverage
    • Corporate Governance
    • Regulated Information
    • Shareholders Information
    • Shareholders Meeting
  • Careers
  • Contact Us

Uncategorized

Celyad Oncology Announces June 2021 Conference Schedule

May 26, 2021 By Celyad Oncology

Mont-Saint-Guibert, Belgium – Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the company plans to participate at the following conferences in June 2021:

Jefferies Virtual Healthcare Conference

Dates: Tuesday, June 1 – Friday June 4, 2021

Presentation date: Tuesday, June 1, 2021

Time: 11:00 a.m. EST / 5:00 p.m. CET

Presenter: Filippo Petti, CEO

Webcast: A webcast of the presentation will be available in the Events section of the Celyad Oncology website.

William Blair & Company Annual Growth Stock Conference

Dates: Tuesday, June 1 – Thursday, June 3, 2021

Presentation date: Wednesday, June 2, 2021

Time: 11:00 a.m. EST / 5:00 p.m. CET

Presenter: Filippo Petti, CEO

Webcast: An archived webcast of the presentation will be available in the Events section of the Celyad Oncology website

JMP Securities Life Sciences Conference

Dates: Wednesday, June 16 – Thursday, June 17, 2021

Presentation date: Thursday, June 17, 2021

Time:  11:30 a.m. EST / 5:30 p.m. CET

Presenter: Filippo Petti, CEO

Kepler Cheuvreux Digital Life Science Day

Date: June 22, 2021

Download press release(s)
Communiqué de presse
Press Release

Filed Under: Press Releases, Uncategorized

Transparency Notification received from Victory Capital Management Inc. (Article 14 §1 of the Law of 2 May 2007)

May 19, 2021 By Celyad Oncology

Mont-Saint-Guibert, Belgium – Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that it has received a transparency notification dated 14 May 2021 indicating that Victory Capital Management Inc., now has crossed the statutory threshold of 5%, holding 713,214 shares i.e. 4.11% of Celyad Oncology’s shares and voting rights as of 13 May 2021.

Content of the Notification:

  • Reason of the Notification:
    • Downward crossing of the lowest threshold
    • Acquisition or disposal of voting securities or voting rights
  • Notification by:
    • A parent undertaking or a controlling person
  • Persons subject to the notification requirement:
    • Victory Capital Holdings, Inc. – 4900 Tiedemann Rd, 4th Floor, Brooklyn, OH, 44144 USA
    • VCH Holdings, LLC – 4900 Tiedemann Rd, 4th Floor, Brooklyn, OH, 44144 USA
    • Victory Capital Operating, LLC – 4900 Tiedemann Rd, 4th Floor, Brooklyn, OH, 44144 USA
    • Victory Capital Management Inc. – 4900 Tiedemann Rd, 4th Floor, Brooklyn, OH, 44144 USA
  • Transaction date
    • May 13th, 2021
  • Threshold that is crossed (in %)
    • 5
  • Denominator
    • 17,373,181
  • Notified details:
A) Voting RightsPrevious notificationAfter the Transaction
 #of voting rights# of voting rights% of voting rights
Holders of voting rights Linked to the securitiesNot linked to the securitiesLinked to the securitiesNot linked to the securities
Victory Capital Holdings Inc.     
VCH Holdings, LLC     
Victory Capital Operating, LLC     
Victory Capital Management, Inc.600,373713,214 4.11% 
Subtotal600,373713,214 4.11% 
 TOTAL713,214 4.11% 
  • Chain of controlled undertakings through which the holdings is effectively held
    • Victory Capital Holdings, Inc controls VCH Holdings, LLC, which controls Victory Capital Operating, LLC, which controls Victory Capital Management Inc., an investment adviser registered with the US. Securities and Exchange Commission.
  • Additional Information
    • Victory Capital Management Inc. is an investment manager who notifies the voting rights for its clients. Victory Capital Management Inc. can exercise the voting rights at its own discretion without any specific instructions from its clients.

Miscellaneous

  • The Press Release may be consulted on the website of Celyad Oncology via this link:
    • https://celyad.com/2021/05/19/transparency-notification-received-from-victory-capital-management-inc-article-14-%c2%a71-of-the-law-of-2-may-2007/
  • The notification can be consulted on the website if Celyad Oncology via this link:
    • https://celyad.com/investors/regulated-information/
  • Contact person(s):
    • By law, any transparency declaration must be sent to our Company by email to the attention of Filippo Petti, Chief Executive Officer (CEO): investors@celyad.com.
Download press release(s)
Communiqué de presse
Press Release

Filed Under: Press Releases, Uncategorized

Celyad Oncology Announces First Quarter 2021 Financial Results and Recent Business Highlights

May 6, 2021 By Celyad Oncology

  • Enrollment continues in second dose cohort of Phase 1 dose-escalation IMMUNICY-1 trial for lead shRNA-based allogeneic CAR T candidate, CYAD-211, for relapsed/refractory multiple myeloma (r/r MM); additional proof-of-concept data anticipated in second quarter 2021.
  • Expansion segment of Phase 1 alloSHRINK trial evaluating allogeneic CYAD-101 administered concurrently with preconditioning chemotherapy for the treatment of advanced metastatic Colorectal Cancer (mCRC) ongoing; preliminary data expected in mid-2021.
  • Phase 1b KEYNOTE-B79 trial evaluating CYAD-101 with KEYTRUDA® in patients with microsatellite stable mCRC expected to be initiated in first half of 2021.

Mont-Saint-Guibert, Belgium – Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the “Company”), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced an update on its financial results and recent business developments for the fiscal quarter ended March 31, 2021.

“We have entered 2021 with ever-increasing enthusiasm around the progress of our programs,” commented Filippo Petti, Chief Executive Officer of Celyad Oncology. “Our lead shRNA-based allogeneic candidate, CYAD-211, which is currently being evaluated in the Phase 1 IMMUNICY-1 trial for the treatment of multiple myeloma, has shown no safety concerns nor evidence of Graft-versus-Host Disease (GvHD) at dose level 1. We look forward to announcing additional proof-of-concept data from this trial by the end of second quarter of 2021. In addition, we have continued to enroll patients in the alloSHRINK expansion trial for CYAD-101 and will turn our attention to the KEYNOTE-B79 trial. Lastly, we are planning an R&D day for this summer that will provide an opportunity for our broader team to offer an in-depth overview of our clinical programs and strategy for advancing our next-generation shRNA platform and allogeneic pipeline.”

Recent Highlights

  • Appointment of Dr. Charles Morris as Chief Medical Officer to lead and provide strategic direction for Celyad Oncology’s medical, regulatory, and clinical development activities.
  • Appointment of Marina Udier, Ph.D. to Board of Directors
  • Announced a committed equity purchase agreement for up to $40 million in American Depositary Shares (ADSs) with Lincoln Park Capital Fund, LLC (“LPC”)


First Quarter 2021 Financial Review

As of March 31, 2021, the Company had cash and cash equivalents of €12.2 million ($14.3 million). Net cash burn during the first quarter of 2021 amounted to €5.1 million ($5.9 million), in line with expectations. In April 2021, the Company raised proceeds of €3.3 million ($4.0 million) from the sale of ADSs to LPC. The Company confirms its previous guidance that its existing cash and cash equivalents combined with the remaining access to the equity purchase agreement established with LPC should be sufficient, based on the current scope of activities, to fund operating expenses and capital expenditure requirements until mid-2022.

Update on Clinical Programs

CYAD-211 – Allogeneic shRNA-based, anti-BCMA CAR T for r/r MM

CYAD-211 is an investigational, shRNA-based allogeneic CAR T candidate engineered to co-express a BCMA-targeting chimeric antigen receptor and a single shRNA, which interferes with the expression of the CD3ζ component of the T-cell receptor (TCR) complex. The Company is currently conducting the first-in-human, open-label, dose-escalation Phase 1 IMMUNICY-1 trial to evaluate the safety and efficacy of a single infusion of CYAD-211 following preconditioning chemotherapy cyclophosphamide and fludarabine in patients with r/r MM. The trial seeks to determine the recommended dose of CYAD-211 for the treatment of patients with r/r MM for further development as well as to establish proof-of-concept that single shRNA-mediated knockdown can generate allogeneic CAR T cells in humans without inducing GvHD. In March, the Company announced that no safety concerns nor evidence of GvHD had been reported in the first three patients treated at dose level 1 (30×106 cells per infusion) of CYAD-211 in the IMMUNICY-1 trial. In first quarter 2021, the Company initiated enrollment in dose level 2 (100×106 cells per infusion). The Company expects to announce additional proof-of-concept data from the IMMUNICY-1 trial by the end of the second quarter of 2021.


CYAD-101 – Allogeneic TIM-based NKG2D CAR T for mCRC

The Company’s first-in-class, non-gene edited clinical candidate, CYAD-101, which co-expresses the NKG2D receptor and the novel inhibitory peptide TCR Inhibitory Molecule (TIM), is currently in the expansion segment of the alloSHRINK Phase 1 trial for the treatment of advanced mCRC. To the Company’s knowledge, CYAD-101 is the first investigational allogeneic CAR T candidate to generate evidence of clinical activity for the treatment of a solid tumor indication.

  • Phase 1 alloSHRINK trial is ongoing, in which the Company is evaluating CYAD-101 following FOLFIRI (combination of 5-fluorouracil, leucovorin and irinotecan) preconditioning chemotherapy in refractory mCRC patients, at the recommended dose of one billion cells per infusion. The Company expects to announce preliminary data from the expansion cohort of the trial in mid-2021.  
  • Celyad Oncology will also conduct the Phase 1b KEYNOTE-B79 clinical trial, which will evaluate Celyad Oncology’s investigational non-gene edited allogeneic CAR T candidate, CYAD-101, following FOLFIRI chemotherapy, with MSD’s anti-PD­1 therapy, KEYTRUDA® (pembrolizumab) in refractory metastatic colorectal cancer (mCRC) patients with microsatellite stable (MSS) / mismatch-repair proficient (pMMR) disease. The Phase 1b KEYNOTE-B79 trial is expected to be initiated during first half of 2021.

CYAD-02 – Autologous NKG2D receptor-based CAR T for relapsed/refractory acute myeloid leukemia (r/r AML) and myelodysplastic syndromes (MDS)

Enrollment is ongoing in dose level 3 of the Phase 1 CYCLE-1 trial for the next-generation, autologous NKG2D receptor-based CAR T candidate CYAD-02. The dose-escalation Phase 1 CYCLE-1 trial is evaluating the safety and clinical activity of CYAD-02 following preconditioning chemotherapy in patients with r/r AML and MDS. To date, treatment with CYAD-02 has been generally well-tolerated. Of seven patients evaluable for clinical activity, five patients demonstrated anti-leukemic activity (at least 50% bone marrow blasts decrease), including a very-high risk MDS patient treated at dose level 3 who achieved a marrow complete response.

Next-generation shRNA Multiplex Platform

In 2020, the Company began developing a proprietary shRNA platform utilizing a novel framework to optimize and expand the expression of multiple shRNAs with our All-in-One vector approach. The Company’s novel framework has the capability to knockdown or silence up to six genes simultaneously, while providing several key advantages beyond the Company’s first-generation approach. The Company believes its next-generation shRNA multiplex platform will form the backbone for future allogeneic CAR T candidates, including several programs which are in the discovery phase of development. Our next-generation shRNA platform does not incorporate any of the Horizon Discovery technology.

Upcoming Milestones

  • Additional proof-of-concept data from the initial dose cohorts of the Phase 1 IMMUNICY-1 trial of CYAD-211 for r/r MM are expected by the end of second quarter of 2021.
  • Preliminary data from the expansion segment of the alloSHRINK trial evaluating CYAD-101 following FOLFIRI preconditioning chemotherapy in refractory mCRC patients are expected in mid-2021.
  • Initiation of the Phase 1b KEYNOTE-B79 trial evaluating CYAD-101 with KEYTRUDA® in mCRC patients with MSS/pMMR disease is anticipated in the first half of 2021.
  • Additional data from dose level 3 of Phase 1 CYCLE-1 trial of CYAD-02 for r/r AML and MDS are anticipated in the first half of 2021.

Financial Calendar

First Half 2021 Financial Results …………………………. August 4, 2021

Third Quarter 2021 Financial Results …………………… November 10, 2021

Download press release(s)
Communiqué de presse
Press Release

Filed Under: Uncategorized

Transparency notification received from Tolefi SA (Article 14 §1 of the Law of 2 May 2007)

May 5, 2021 By Celyad Oncology

Mont-Saint-Guibert, Belgium – Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that it has received a transparency notification from Tolefi SA, dated 3 May 2021.

Tolefi SA has notified that its 2.295.701 shares benefit from a double voting right as of May 3, 2021 and that its shareholding has crossed above the threshold of 25%. The full transparency notice is available on the Celyad website under the heading “Regulated Information”.

Download press release(s)
Communiqué de presse
Press Release

Filed Under: Uncategorized

Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

May 4, 2021 By Celyad Oncology

Mont-Saint-Guibert, Belgium – Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, announced that Tolefi SA’s shares benefit from a double voting right as of May 3, 2021. As a result, the Company’s total number of voting rights is now 17,373,181.

This information is published in accordance with Article 15 of the Belgian Law of 2 May 2007 on the disclosure of major participations in issuers whose shares are admitted to trading on a regulated market and regarding miscellaneous provisions.

Figures – Modified on 3 May 2021 following the Double Voting Rights:

Total amount of share capital (EUR)52,211,200.33
Total Number of shares with single voting rights12,637,131
Total Number of shares with double voting rights2,368,025
Total Number of Shares15,005,156
Total of voting rights17,373,181
Total number of attributed warrants1,802,756
Total number of shares with voting rights that could be created following the exercise of the attributed warrants1,802,756
Total number of diluted shares (Outstanding shares + Warrants)16,807,912
Total number of diluted shares with voting rights19.175.937

Contact person for regulated information (financial, transparency)

By law, any transparency declaration must be sent to our Company by email to the attention of Filippo Petti, Chief Executive Officer (CEO): investors@celyad.com.

Further questions about the content of this release can be sent to investors@celyad.com.

Download press release(s)
Communiqué de presse
Press Release

Filed Under: Uncategorized

Celyad Oncology Appoints Dr. Charles Morris as Chief Medical Officer

April 19, 2021 By Celyad Oncology

Mont-Saint-Guibert, Belgium – Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, announced the appointment of Dr. Charles Morris to the position of Chief Medical Officer. Dr. Morris will lead and provide strategic direction for all medical, regulatory and clinical development activities.

“We are delighted to bring someone with Dr. Morris’s vast expertise and experience on board during this pivotal time in the Company,” said Filippo Petti, CEO of Celyad Oncology. “Dr. Morris has played an integral part in guiding multiple late-stage oncology drugs to approval and his demonstrated track record of leadership in the pharmaceutical industry will greatly benefit the work we are doing at Celyad Oncology.”

Dr. Morris said, “I’m happy to be joining Celyad Oncology during such a milestone rich year full of multiple important data readouts. Celyad Oncology’s unique allogeneic CAR T approach coupled with its proprietary allogeneic technologies provides a wealth of material to create a differentiated pipeline for patients with unmet medical needs. I look forward to working with the team to advance Celyad Oncology and help make it a leader in the field.”

Dr. Morris is a medical oncologist with over 20 years of oncology drug development experience in the international biotech and pharmaceutical space. Prior to joining Celyad Oncology, Dr. Morris served as Chief Medical Officer of Radius Health and held leadership positions at PsiOxus Therapeutics, ImmunoGen Inc and Allos Therapeutics, where he contributed to all phases of development for solid and hematological tumor indications, as well as life-cycle management development activities for FOLOTYN (pralatrexate) while at Allos. Before serving in these positions, he was Vice President of Worldwide Clinical Research at Cephalon, Inc., where he helped the company achieve its first oncology drug approval for Treanda® (bendamustine). He spent the early years of his career in various roles at AstraZeneca, where he significantly contributed to the worldwide development of Faslodex (fulvestrant), co-authored multiple publications regarding fulvestrant and breast cancer, and supported early clinical development activities for Iressa® (gefitinib).

Dr. Morris holds a Bachelor of Medicine, Bachelor of Surgery and Bachelor of Medical Science in Clinical Pharmacology and Therapeutics degree from Sheffield University Medical School in the UK and is a Member of the Royal College of Physicians of London.

Download press release(s)
Communiqué de presse
Press Release

Filed Under: Uncategorized

  • « Go to Previous Page
  • Go to page 1
  • Interim pages omitted …
  • Go to page 6
  • Go to page 7
  • Go to page 8
  • Go to page 9
  • Go to page 10
  • Interim pages omitted …
  • Go to page 13
  • Go to Next Page »

Footer

Celyad Oncology

Celyad Oncology Logo
  • About
  • Science
  • Pipeline
  • Newsroom
  • Investors
  • Contact Us
  • LinkedIn
  • Twitter

Copyright © 2020 All Rights Reserved.

  • Cookie Policy |
  • Privacy Policy |
  • Terms of Use